Slammed by more deaths, Seat­tle Ge­net­ics scraps a PhI­II study and pulls back (again) on vadas­tux­imab

Just three months af­ter the FDA lift­ed a clin­i­cal hold on its late-stage can­cer drug vadas­tux­imab talirine (SGN-CD33A), the biotech abrupt­ly scrapped a Phase III study and halt­ed en­roll­ment across a slate of stud­ies af­ter in­de­pen­dent mon­i­tors tracked a high­er rate of deaths among pa­tients tak­ing its drug.

The deaths in the study — for front­line use against acute myeloid leukemia — in­clud­ed fa­tal in­fec­tions but were ev­i­dent­ly not as­so­ci­at­ed with liv­er tox­i­c­i­ty, which had al­ready killed 4 pa­tients, forc­ing the FDA to hit the brakes on the study in late De­cem­ber, 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.